Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Hepatitis market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

6 Item(s)

Page 1 of 1

  1. Global Hepatitis Drugs Market 2015-2019

    By: Technavio
    , Published: Dec-2015
    , Product code: IRTNTR6912
    TechNavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.
    $3,000.00

  2. Global Viral Hepatitis and Retrovirus Diagnostic Tests Market 2015-2019

    By: Technavio
    , Published: Oct-2015
    , Product code: IRTNTR7415
    This report covers the present scenario and the growth prospects of the craft beer market in the US for the period 2015-2019. To calculate the market size, this report includes revenue generated from the sales of the following craft beer:
    $2,500.00

  3. Hepatitis C - Pipeline Review, H1 2015

    By: Global Markets Direct
    , Published: Jan-2015
    , Product code: GMDHC6008IDB
    Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2015’, provides an overview of the Hepatitis C’s therapeutic pipeline.
    $2,000.00

  4. Global Hepatitis C Market 2014-2018

    By: Technavio
    , Published: Sep-2014
    , Product code: IRTNTR4050
    About Hepatitis C Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.
    $3,000.00

  5. Global Hepatitis B Vaccines Market 2014-2018

    By: Technavio
    , Published: Aug-2014
    , Product code: IRTNTR3995
    About Hepatitis B Vaccines Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines.
    $2,500.00

  6. Trends in Therapeutic Partnering

    By: Current Partnering
    , Published: Aug-2014
    , Product code: CP2290-
    Provides a detailed understanding and analysis of the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014
    $3,995.00

6 Item(s)

Page 1 of 1